Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Breast Neoplasms
/ drug therapy
Case-Control Studies
Cell Line, Tumor
Drug Synergism
Female
Histone Deacetylase Inhibitors
/ administration & dosage
Humans
Phagocytosis
/ drug effects
Prognosis
Receptor, ErbB-2
/ antagonists & inhibitors
Receptors, IgG
/ metabolism
Trastuzumab
/ administration & dosage
Valproic Acid
/ administration & dosage
Vorinostat
/ administration & dosage
immunology
medicine
oncology
tumours
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
accepted:
01
11
2019
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
3
11
2020
Statut:
ppublish
Résumé
The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb trastuzumab. Histone deacetylase inhibitors (HDACi), such as valproic acid (VPA) or vorinostat (SAHA), exert several immunostimulatory properties, which contribute at least in part to their anticancer effect. However, the impact of HDACi-induced immunostimulatory effects on trastuzumab-mediated anti-tumor immune response is not well characterized. We analyzed the ADCP and ADCC activity of peripheral blood mononuclear cells (PBMCs) from age and gender-matched healthy volunteers (n=5) against HDACi-treated HER2-overexpressing breast cancer cells (SKBR3), using a well-established in vitro three-color imaging flow cytometry and flow cytometry approach. VPA and SAHA enhanced trastuzumab-mediated ADCP and trastuzumab-independent cytotoxicity. Mechanistically, VPA upregulated the activating antibody-binding receptor Fc-gamma receptor (FcγR) IIA (CD32A) on monocytes (CD14+). Moreover, VPA and SAHA downregulated the anti-apoptotic protein myeloid leukemia cell differentiation 1 (MCL1) in breast cancer cells. Additionally, VPA and SAHA induced an immunogenic cell death, characterized by the exposure of calreticulin (CALR), as well as decreased the "do not eat me" signal CD47 on tumor cells. HDACi VPA and SAHA increase trastuzumab-mediated phagocytosis and trastuzumab-independent cytotoxicity. The immunomodulatory activities of those HDACi support a rationale combined treatment approach with mAb for cancer treatment.
Sections du résumé
BACKGROUND
The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb trastuzumab. Histone deacetylase inhibitors (HDACi), such as valproic acid (VPA) or vorinostat (SAHA), exert several immunostimulatory properties, which contribute at least in part to their anticancer effect. However, the impact of HDACi-induced immunostimulatory effects on trastuzumab-mediated anti-tumor immune response is not well characterized.
METHODS
We analyzed the ADCP and ADCC activity of peripheral blood mononuclear cells (PBMCs) from age and gender-matched healthy volunteers (n=5) against HDACi-treated HER2-overexpressing breast cancer cells (SKBR3), using a well-established in vitro three-color imaging flow cytometry and flow cytometry approach.
RESULTS
VPA and SAHA enhanced trastuzumab-mediated ADCP and trastuzumab-independent cytotoxicity. Mechanistically, VPA upregulated the activating antibody-binding receptor Fc-gamma receptor (FcγR) IIA (CD32A) on monocytes (CD14+). Moreover, VPA and SAHA downregulated the anti-apoptotic protein myeloid leukemia cell differentiation 1 (MCL1) in breast cancer cells. Additionally, VPA and SAHA induced an immunogenic cell death, characterized by the exposure of calreticulin (CALR), as well as decreased the "do not eat me" signal CD47 on tumor cells.
CONCLUSIONS
HDACi VPA and SAHA increase trastuzumab-mediated phagocytosis and trastuzumab-independent cytotoxicity. The immunomodulatory activities of those HDACi support a rationale combined treatment approach with mAb for cancer treatment.
Identifiants
pubmed: 31940587
pii: jitc-2019-000195
doi: 10.1136/jitc-2019-000195
pmc: PMC7057438
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
FCGR2A protein, human
0
Histone Deacetylase Inhibitors
0
Receptors, IgG
0
Vorinostat
58IFB293JI
Valproic Acid
614OI1Z5WI
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Front Oncol. 2012 Jun 18;2:62
pubmed: 22720269
J Clin Oncol. 2009 Jun 20;27(18):2962-9
pubmed: 19364966
Cancer Lett. 2011 Aug 1;307(1):72-79
pubmed: 21497990
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Nat Med. 2015 Oct;21(10):1209-15
pubmed: 26322579
Oncogene. 2013 Jun 6;32(23):2873-81
pubmed: 22797062
Nat Rev Cancer. 2019 Mar;19(3):151-161
pubmed: 30723290
Cancer Res. 2013 Dec 15;73(24):7265-76
pubmed: 24158093
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
J Immunol Methods. 2007 Jun 30;323(2):160-71
pubmed: 17531261
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Clin Cancer Res. 2004 May 15;10(10):3542-51
pubmed: 15161714
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Clin Cancer Res. 2005 Sep 1;11(17):6382-9
pubmed: 16144943
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
Cancer Res. 2005 Dec 1;65(23):11136-45
pubmed: 16322264
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
J Immunol. 2015 May 1;194(9):4379-86
pubmed: 25795760
Cell Death Dis. 2013 Feb 28;4:e519
pubmed: 23449455
Ann Oncol. 2012 Jul;23(7):1788-95
pubmed: 22056974
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Br J Cancer. 2019 Jun;120(12):1105-1112
pubmed: 31097774
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4141-6
pubmed: 21368108
Mol Cancer Ther. 2008 Aug;7(8):2517-27
pubmed: 18723496
Mol Cancer Ther. 2003 Oct;2(10):971-84
pubmed: 14578462
N Engl J Med. 2007 Oct 18;357(16):1664-5; author reply 1665-6
pubmed: 17948347
J Clin Invest. 2014 Jan;124(1):30-9
pubmed: 24382387
Trends Immunol. 2018 Mar;39(3):173-184
pubmed: 29336991
Cancer Res. 2017 May 15;77(10):2594-2606
pubmed: 28249907
ACS Chem Biol. 2013 Feb 15;8(2):368-75
pubmed: 23030766
J Transl Med. 2013 Dec 12;11:307
pubmed: 24330813
Breast Cancer Res. 2015 Jan 30;17:13
pubmed: 25633049
Cancer Res. 2004 Feb 1;64(3):1079-86
pubmed: 14871841
Ann Oncol. 2013 Nov;24(11):2761-6
pubmed: 23894039
Nat Biotechnol. 2007 Jan;25(1):84-90
pubmed: 17211407
Cancer Immunol Immunother. 2009 Jun;58(6):915-30
pubmed: 18941743
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53
pubmed: 16467098
EMBO J. 2001 Dec 17;20(24):6969-78
pubmed: 11742974
Nat Immunol. 2014 Aug;15(8):707-16
pubmed: 25045879
Cell. 2018 Oct 4;175(2):442-457.e23
pubmed: 30290143
Int J Mol Med. 2011 Dec;28(6):985-91
pubmed: 21887460
J Immunol Methods. 2011 May 31;368(1-2):54-63
pubmed: 21420412
J Clin Oncol. 2005 Apr 1;23(10):2162-71
pubmed: 15800309
Sci Transl Med. 2010 Dec 22;2(63):63ra94
pubmed: 21178137
Cancer Res. 2005 Jul 15;65(14):6321-9
pubmed: 16024634
J Clin Oncol. 2010 Oct 1;28(28):4307-15
pubmed: 20697084
Breast Cancer Res Treat. 2017 Sep;165(2):375-382
pubmed: 28623430
J Clin Oncol. 2009 Dec 1;27(34):5838-47
pubmed: 19884552
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8
pubmed: 23690610